论文部分内容阅读
目的:探究检测血清肿瘤标志物对预测晚期非小细胞肺癌靶向治疗预后的影响。方法:选取2010年4月至2012年12我院收治的晚期非小细胞肺癌患者70例,均予以吉非替尼进行治疗,检测治疗前及治疗后2个月肿瘤标志物癌胚抗原CEA、角蛋白19的可溶性片段(CYFRA21-1)、癌抗原125(CA125)的表达水平,观察其表达水平与患者疗效之间的关系。结果:治疗后,患者完全缓解1例,部分缓解37例,疾病稳定19例,疾病进展13例,有效率为54.3%。治疗后,治疗有效的患者CEA、CA125明显比治疗前降低,结果具有统计学意义(P<0.05);而疾病稳定、疾病进展的患者治疗后CEA、CA125与治疗前比却无明显差异(P>0.05)。治疗有效与疾病稳定的患者治疗后CYFRA21-1有明显降低,但与治疗前比却无明显差异(P>0.05);而疾病进展患者的CYFRA21-1却明显升高,与治疗前比有显著差异(P<0.05)。而治疗前,治疗有效的患者血清中CEA、CA125比疾病稳定、疾病进展的患者明显较高,结果具有统计学意义(P<0.05);疾病稳定患者的CEA、CA125与疾病进展患者的相比,治疗有效的患者CYFRA21-1与疾病稳定、疾病进展的相比,结果均不具有统计学意义(P>0.05)。结论:治疗前CEA、CA125浓度较高则治疗效果不错,治疗后效果较好则CEA、CA125浓度较低,效果不好则CYFRA21-1浓度较高。利用血清肿瘤标志物可显著反映肿瘤靶向药物治疗的预后情况,为临床判断其治疗效果提供依据。
Objective: To explore the effect of serum tumor markers on prognosis of advanced non-small cell lung cancer targeted therapy. Methods: From April 2010 to December 2012, 70 patients with advanced non-small cell lung cancer admitted to our hospital were treated with gefitinib. The tumor markers carcinoembryonic antigen CEA, The expression of keratin 19 soluble fragment (CYFRA21-1) and cancer antigen 125 (CA125) were observed. The relationship between the expression level and the curative effect was observed. Results: After treatment, complete remission in 1 patient, partial remission in 37 cases, stable disease in 19 cases, disease progression in 13 cases, the effective rate was 54.3%. After treatment, the effective therapeutic patients CEA, CA125 was significantly lower than before treatment, the results were statistically significant (P <0.05); and stable disease, disease progression in patients with post-treatment CEA, CA125 compared with before treatment there was no significant difference (P > 0.05). The patients with effective treatment and stable disease had significantly lower CYFRA21-1 after treatment than those before treatment (P> 0.05), while CYFRA21-1 in patients with advanced disease was significantly higher than that before treatment Difference (P <0.05). Before treatment, the patients with effective treatment had significantly higher CEA and CA125 levels than the patients with stable disease and disease progression (P <0.05). Compared with patients with stable disease, the levels of CEA and CA125 in patients with stable disease were significantly higher than those with stable disease , The effective treatment of patients with CYFRA21-1 stable disease, disease progression compared to the results were not statistically significant (P> 0.05). Conclusions: The high concentration of CEA and CA125 before treatment is good, the effect is good after treatment, while the concentration of CEA and CA125 is lower, and the effect is not good, while the concentration of CYFRA21-1 is higher. The use of serum tumor markers can significantly reflect the prognosis of tumor-targeted drug therapy for clinical judgment of the treatment effect.